Abstract:We agree with the concerns raised by Eastwood and Schlossenberg about the changing drug landscape in the UK.1 There is a need in healthcare for a functional surveillance system to identify emerging threats.Regrettably, the availability of analytical toxicology services in the NHS is exceptionally disparate. Apart from a few very specialist laboratories, a significant amount of NHS toxicology testing is either point-of-care immunoassays which have poor sensitivity, or targeted mass spectrometric methods which detect only a limited number of drugs. These methods are unlikely to be able to detect newer compounds and are unlikely to be responsive enough to the ever changing nature of the emerging novel opioid picture. Isotonitazene is one such compound, but many others have now been detected in the UK, posing a significant analytical challenge.Another concern is that clinicians requesting toxicology analysis may have no idea what drugs are included in the scope of a screen—a...

Illegal drugs in the UK—we need better screening and surveillance